New hope for elderly lymphoma patients: drug combo shows promise in early trial
NCT ID NCT07397832
First seen Mar 12, 2026 · Last updated May 24, 2026 · Updated 8 times
Summary
This study tests a new combination of three drugs (chidamide, rituximab, and polatuzumab vedotin) in elderly patients with a specific type of lymphoma called double-positive DLBCL. The goal is to see how well the treatment shrinks tumors and controls the disease. About 58 people aged 60 or older who have not had prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Insititute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.